Researchers identify new blood marker for dopamine system damage

The marker in question is called DOPA decarboxylase (DCC). In the current study, DCC was found to be elevated in individuals with Parkinson’s disease as well as in people with other diseases that result in dopamine deficiency in the brain. However, the marker was normal in other brain diseases such as Alzheimer’s disease. The researchers even noticed that DCC was elevated in individuals with Parkinson’s many years before they developed any symptoms.

J&J touts success of Vyvgart competitor in two autoimmune disease trials, including key myasthenia gravis study

Johnson & Johnson’s experimental antibody nipocalimab reduced the severity of symptoms related to two autoimmune conditions — first in a pivotal study for generalized myasthenia

February 6, 2024

Study discovers method to classify febrile illness with a single blood sample

Researchers trained machine learning (ML) models to analyze RNA molecular signatures in patients’ blood.

August 28, 2023

HBO’s ‘The Last of Us’ fungal apocalypse, science fiction, not future reality

Researchers in “Emerging Infectious Diseases” debunk the scenario of a global fungal pandemic as depicted in HBO’s ‘The Last of Us,’ citing slow fungal evolution

February 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.